Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease.
Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
The company is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 21, 23 | -3.34 Decreased by -5.46 K% | - |
| May 15, 23 | -0.06 Increased by +14.29% | - |
| Mar 16, 23 | -0.02 Increased by +66.67% | -0.02 |
| Nov 14, 22 | -0.03 Increased by +72.73% | -0.03 |
| Aug 10, 22 | -0.06 Decreased by -50.00% | -0.04 Decreased by -50.00% |
| May 16, 22 | -0.07 Increased by +70.83% | -0.03 Decreased by -133.33% |
| Mar 31, 22 | -0.06 Increased by +75.00% | -0.04 Decreased by -50.00% |
| Nov 22, 21 | -0.11 Decreased by -10.00% | -0.04 Decreased by -175.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.06 M Increased by +501.85% | 348.20 K Increased by +107.92% | Increased by +3.84% Increased by +101.32% |
| Jun 30, 23 | 6.95 K Decreased by -82.57% | -8.57 M Decreased by -2.11% | Decreased by -123.46 K% Decreased by -485.84% |
| Mar 31, 23 | 1.45 M Increased by +25.85% | 71.70 K Increased by +100.69% | Increased by +4.93% Increased by +100.55% |
| Dec 31, 22 | 2.15 M Increased by +285.49% | -3.40 M Increased by +61.22% | Decreased by -158.23% Decreased by -120.91% |
| Sep 30, 22 | 1.51 M Decreased by -63.35% | -4.40 M Increased by +71.40% | Decreased by -292.15% Increased by +21.95% |
| Jun 30, 22 | 39.85 K Decreased by -99.01% | -8.40 M Increased by +9.84% | Decreased by -21.07 K% Decreased by -8.98 K% |
| Mar 31, 22 | 1.15 M Decreased by -68.26% | -10.35 M Increased by +49.17% | Decreased by -896.88% Decreased by -60.15% |
| Dec 31, 21 | -1.16 M Decreased by -131.88% | -8.77 M Increased by +56.93% | Increased by +756.76% Increased by +235.13% |